INS and Insulin resistance: Analysis of metabolic parameters revealed that compared with MET-free counterparts, MET-treated patients had similar levels of fasting glycemia and insulin secretion (C-peptide level), but larger Hb1Ac level, higher insulin and glucagon level and more pronounced insulin resistance (HOMA-IR), Table 1 and Fig. 1.